Kite, A Gilead Company, Received FDA Approval Of Manufacturing Process Change Resulting In Reduced Median Turnaround Time For Yescarta CAR T-cell Therapy

Gilead Sciences, Inc. -0.69% Pre

Gilead Sciences, Inc.





0.00% Pre

– New Median Turnaround Time from Leukapheresis to Product Release in U.S. Anticipated to be Reduced from 16 Days to 14 Days –

– Continues to Support Kite's Industry-Leading Overall Turnaround Time and Reliability –

– Time to Treatment is a Critical Factor for CAR T-cell Therapy Patients –

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via